This is a Phase I/II trial for safety and preliminary efficacy of the combination of axitinib
and selenomethionine (SLM) for adult patients with advanced metastatic clear cell renal cell
carcinoma (CCRCC). This will be a two part study consisting of a dose escalation and
expansion study.
In addition, a pilot group of 10 subjects will have SLM dose calculated based on patients'
body surface area (BSA) to characterize the dose-concentration relationship and estimate the
effective administered dose of selenium necessary to achieve the target blood concentration
range informed by preclinical data.